{"id":77841,"date":"2024-03-13T04:29:05","date_gmt":"2024-03-13T09:29:05","guid":{"rendered":"https:\/\/equitynewsreport.com\/natures-sunshine-products-stock-target-raised-to-24-on-ebitda-beat\/"},"modified":"2024-03-13T04:29:05","modified_gmt":"2024-03-13T09:29:05","slug":"natures-sunshine-products-stock-target-raised-to-24-on-ebitda-beat","status":"publish","type":"post","link":"https:\/\/equitynewsreport.com\/h\/natures-sunshine-products-stock-target-raised-to-24-on-ebitda-beat\/","title":{"rendered":"Nature&#8217;s Sunshine Products stock target raised to $24 on EBITDA beat"},"content":{"rendered":"<div readability=\"68\">\n<div id=\"imgCarousel\" class=\"imgCarousel\">\n<img decoding=\"async\" alt=\"Nature's Sunshine Products stock target raised to $24 on EBITDA beat\" id=\"carouselImage\" src=\"https:\/\/i-invdn-com.investing.com\/news\/LYNXMPEA6606G_L.jpg\"><br \/>\n<span class=\"text\">\u00a9 Reuters. <\/span><br \/>\n<i class=\"imgGrad\"><\/i>\n<\/div>\n<p>On Wednesday, DA Davidson maintained a bullish stance on Nature&#8217;s Sunshine Products (NASDAQ: NATR), raising the stock&#8217;s price target to $24.00 from $21.50 and keeping a Buy rating. <\/p>\n<p>The nutritional and wellness products company reported a stronger-than-expected performance in the fourth quarter of 2023, with EBITDA surpassing estimates. Sales in constant currency terms increased by 6% overall, with three out of four major regions experiencing growth.<\/p>\n<p>The company saw a significant improvement in its North American market, where constant currency sales grew by 13%, up from an 11% increase in the third quarter of 2023. This growth came despite a challenging comparison with the previous year. Digital sales in North America were particularly strong, showing a 97% year-over-year increase and accounting for approximately 25% of the region&#8217;s total sales.<\/p>\n<p>Looking ahead, Nature&#8217;s Sunshine Products has provided guidance for 2024, expecting constant currency sales to rise between 3% and 9%. In response to this positive outlook, DA Davidson has adjusted its sales estimate upwards and increased its EBITDA projection by 10% to $45.2 million, which would represent a 12% year-over-year increase.<\/p>\n<p>The long-term financial targets for Nature&#8217;s Sunshine Products include achieving a mid- to high-double digit EBITDA margin, compared to the 9.1% margin recorded in 2023. The revised price target of $24.00 is based on a 7.5 times multiple of the anticipated 2025 EBITDA, which has been increased from the previous estimate of $44.8 million to $49.7 million.<\/p>\n<p><em>This article was generated with the support of AI and reviewed by an editor. For more information see our T&#038;C.<\/em><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>\u00a9 Reuters. On Wednesday, DA Davidson maintained a bullish stance on Nature&#8217;s Sunshine Products (NASDAQ: NATR), raising the stock&#8217;s price target to $24.00 from $21.50 and keeping a Buy rating. The nutritional and wellness products company reported a stronger-than-expected performance in the fourth quarter of 2023, with EBITDA surpassing estimates. Sales in constant currency terms increased by 6% overall, with three out of four major regions experiencing growth. The company saw a significant improvement in its North American market, where constant currency sales grew by 13%, up from an 11% increase in the third quarter of 2023. This growth came [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":77842,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[50,48,49,3],"tags":[],"_links":{"self":[{"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/posts\/77841"}],"collection":[{"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/comments?post=77841"}],"version-history":[{"count":0,"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/posts\/77841\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/media\/77842"}],"wp:attachment":[{"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/media?parent=77841"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/categories?post=77841"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/tags?post=77841"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}